



VIA HAND DELIVERY MARCH 14, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Moore et al.

Attorney Docket No.: PZ032P1C3

Serial No.: 10/054,988

Group Art Unit: Unassigned

Filed: Herewith

Examiner: Unassigned

Title: **49 Human Secreted Proteins**

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to document AW, a Supplemental Partial European Search Report, mailed February 15, 2002, listed on the attached Form PTO/SB/08. A copy of document AW is enclosed.

The listed document is directed to a gene that is different from the one being pursued in this application. Nevertheless, under 37 C.F.R. § 1.56, Applicant's wish to draw the Examiner's attention to this document. At the Examiner's request, a copy of the references cited in the Supplementary Partial European Search Report can be provided.

Accordingly, the undersigned certifies, pursuant to 37 C.F.R. § 1.97(e)(1), that this item of information was forwarded in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.


The listed reference is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed reference of record in the file

history of the application and consider the information contained therein during the prosecution of this application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Respectfully submitted,

Date: March 14, 2002


Janet M. Martineau Reg. No. 46,903
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone: (301) 315-2723

JMM/ CEW/mm

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/054,988
				Filing Date	January 25, 2002
				First Named Inventor	Unassigned
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PZ032P1C3
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (known)	Kind Code ² (if			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³ known)	Number ⁴	Kind Code ⁵ (if			

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**